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Toll-like receptor 4 (TLR4), a receptor for damage-associated
molecular pattern molecules and also the lipopolysaccharide
receptor, is required for early endothelial activation leading
to maximal inflammation and injury during murine ischemic
acute kidney injury. DNA microarray analysis of ischemic
kidneys from TLR4-sufficient and -deficient mice showed that
pentraxin 3 (PTX3) was upregulated only on the former while
transgenic knockout of PTX3 ameliorated acute kidney injury.
PTX3 was expressed predominantly on peritubular
endothelia of the outer medulla of the kidney in control mice.
Acute kidney injury increased PTX3 protein in the kidney and
the plasma where it may be a biomarker of the injury.
Stimulation by hydrogen peroxide, or the TLR4 ligands
recombinant human high-mobility group protein B1 or
lipopolysaccharide, induced PTX3 expression in the Mile Sven
1 endothelial cell line and in primary renal endothelial cells,
suggesting that endothelial PTX3 was induced by pathways
involving TLR4 and reactive oxygen species. This increase
was inhibited by conditional endothelial knockout of myeloid
differentiation primary response gene 88, a mediator of a
TLR4 intracellular signaling pathway. Compared to wild-type
mice, PTX3 knockout mice had decreased endothelial
expression of cell adhesion molecules at 4 h of reperfusion,
possibly contributing to a decreased early maladaptive
inflammation in the kidneys of knockout mice. At 24h of
reperfusion, PTX3 knockout increased expression of
endothelial adhesion molecules when regulatory and
reparative leukocytes enter the kidney. Thus, endothelial
PTX3 plays a pivotal role in the pathogenesis of ischemic
acute kidney injury.
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Although ischemic acute kidney injury (AKI) continues to
have a high incidence and mortality despite modern
supportive therapy, and leads to progressive kidney disease
that has its own high mortality,1–3 the pathogenesis remains
poorly understood.
Toll-like receptor 4 (TLR4) is required for the inflamma-
tory response that exacerbates the initial ischemic injury.4 We
previously showed that HMGB1 released by injured renal
cells bound endothelial TLR4, and this increased the
expression of proinflammatory adhesion molecules.5 In the
absence of endothelial TLR4, these adhesion molecules were
not expressed, inflammation was decreased, and injury
ameliorated. These data incriminate TLR4 as the trigger for
the initial endothelial activation necessary for inflammation
and maximal injury during ischemic injury. To better
understand the maladaptive role of TLR4, we compared
genome-wide gene expression at 4 h of reperfusion in kidneys
from wild-type (WT) C57BL/10 mice vs. TLR4-null
C57BL/10ScNJ mice using Affymetrix GeneChip Mouse
Genome 430 2.0 Array chips. One of the most differentially
expressed genes was pentraxin 3 (PTX3; see NCBI Gene
Expression Omnibus (Edgar), GEO Series accession number
GSE34351 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE34351)).
We now report that knockout (KO) of PTX3 ameliorates
ischemic AKI. PTX3 is the prototypic member of the long
pentraxin family that is produced in peripheral tissues. It is
conserved from arachnids to humans. In particular, its gene
organization, structure, and promoter are highly conserved in
humans and mice. This not only suggests the fundamental
importance of PTX3 in biology and disease, but also that
translation of murine studies to human disease should be
possible.6 Although PTX3 increases in human plasma after
acute ischemia–reperfusion injury (IRI) to the brain and
heart, and although this increase is proposed as a clinically
useful and early reliable prognostic marker for bad out-
comes,7,8 whether and how PTX3 contributes to pathophy-
siology of IRI is not well established.
Altogether, the above data suggest fundamental important
links between TLR4, endothelium, and PTX3 in the
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pathophysiology of renal AKI. We now explore these links for
the first time experimentally. We localize PTX3 to renal
endothelium, explore its regulation by reactive oxygen species
(ROS), TLR4, and the Myd88-dependent signaling pathway
of TLR4, and determine the effect of PTX3 KO on endothelial
functions. Our data establish a maladaptive role for PTX3
during ischemic AKI.
RESULTS
PTX3 KO attenuates ischemic AKI
We compared the response of WT vs. PTX3 homozygous KO
(PTX3 KO) kidneys to IRI caused by temporarily occluding the
renal pedicle (see ‘Materials and Methods’). At 24-h reperfusion,
both measures of renal function increased significantly in WT
mice compared with PTX3 KO mice (Figure 1a and b). For
sham-operated mice, the renal function remained similar and
close to baseline in both strains (data not shown).
Note that we used capillary electrophoresis to measure the
serum creatinine (Scr).9 This is more accurate than the usual
Jaffe method, which is confounded by extraneous chromo-
phores in murine serum. Thus, values obtained by direct
chemical measurements (HPLC and capillary electrophoresis)
are 1/6th of the values obtained by the Jaffe-type measure-
ments.10,11 A rise of the Scr from 0.1 to 0.4 mg/dl in our assay
represents significant renal injury. In Figure 1, we used an
ischemia time of 16 min that allowed all the WT mice to
survive for the entire 7-day experiment. We observed the same
protection by PTX3 KO after a 23-min ischemia time, but
some WT mice died. In most experiments in which kidneys
were harvested at 4 h and survival of the WT beyond 24 h was
not important, we used the 23-min ischemia time because this
gave a larger signal for PTX3 and the other proinflammatory
molecules in the WT groups.
We also analyzed the histology of the kidneys by scoring the
tubular damage and inflammation. After IRI, we observed less
injury and inflammation in PTX3 KO ischemic kidneys.
Kidney injury scores were significantly more severe in the WT
compared with PTX3 KO kidneys (Figure 1c and d). To study
leukocyte infiltration, we stained kidney sections with
myeloperoxidase and counted positively staining cells per 10
high-power fields. WT kidneys had significantly more
inflammation (Figure 1c and e).
PTX3 is increased in ischemic WT kidneys but not in
TLR4 KO kidneys
We found that IRI increased PTX3 protein in WT kidneys by
ELISA. At 4-h reperfusion, PTX3 increased by 2.1-fold
compared with sham controls (14.0±1.1 vs. 6.5±0.6 ng/ml).
It reached a peak value of 45±2.5 ng/ml on day 1 (vs. sham
16.0±1.1 ng/ml) and then gradually dropped down to baseline
by day 7 (Figure 2a). In addition, we found a significant
elevation of plasma PTX3 at 4-h reperfusion (96±5.6 vs.
60±4.2 ng/ml), which peaked at 24-h reperfusion (265±9.8
vs. 202±7.3 ng/ml; Figure 2b). This increase is similar to
increases seen after ischemic injury of other organs—brain
after stroke and myocardial ischemia.7,8 Because PTX3 is
produced at the site of injury,6 the plasma PTX3 is thought to
enter the blood from the injured brain, heart, or, in our
experiment, kidney. The increased plasma PTX3 in the sham
mice may represent PTX3 produced by skin, muscle, and
connective tissues that are injured by the surgery necessary to
expose and then place the vascular clamp across (IRI) or
beneath (sham) the renal arteries.
The increase in plasma PTX3 at 4-h reperfusion may be
particularly important. See points enclosed in box in Figure
2b. This increase occurs in the IRI group well before the
increase in the sham group, and well before the increase in
Scr in our AKI model. This suggests that PTX3 may be a
biomarker for the early detection of AKI. The search for such
biomarkers, which appear before an increase in Scr, is a major
ongoing effort in nephrology.12
We previously showed the importance of endothelial
TLR4 in the pathogenesis of ischemic AKI. DNA microarray
data suggested that PTX3 increased on WT ischemic kidneys.
Further quantitative reverse transcription PCR confirmed
that IRI increased renal PTX3 and ESM1 (endothelial cell–
specific molecule 1, or endocan) messenger RNA by 8.27±
0.75-fold and 3.35±0.55-fold, respectively, in WT kidneys.
However, TLR4 KO prevented such increases (Figure 3a and b).
We also compared PTX3 protein expression in sham
kidneys with that in ischemic WT kidneys by immunohisto-
logy. Consistent with the increase in PTX3 messenger RNA,
Figure 3c shows increased peritubular PTX3 protein in the
outer medulla at 4-h reperfusion in WT kidneys. In the TLR4
KO mice, we did not see such increases. Supplementary
Figure S1 online shows that the anti-PTX3 antibody was
specific because there was negligible staining of ischemic
PTX3 KO kidneys.
PTX3 is expressed predominantly on renal endothelia
As PTX3 was upregulated early during AKI, we performed
immunostaining on frozen sections at 4-h reperfusion.
In the sham kidney harvested 4 h after reperfusion, we found
PTX3 on peritubular structures of the outer medulla
(Figure 4a). In addition, there was scattered rare peritubular
staining in the cortico–medullary junction, and we did not
detect PTX3 on glomeruli (Figure 4a). No PTX3 was seen in
the inner medulla (not shown). We localized PTX3 to
peritubular endothelia by double staining with PTX3 and
the endothelial marker CD31 (Figure 4b and Supplementary
Figure S2 online). Previous studies in the kidney after IRI
confirmed CD31 as an appropriate marker of endothelia.13,14
At 4 h after IRI, PTX3 increased on the kidney. There was new
expression of PTX3 on glomerular endothelia and on inner
medulla in addition to increased expression in the outer
medulla (Figure 4c). For high resolution photomicrographs of
Figure 4, please see Supplementary Figure S5 online.
In addition to immunohistology, we developed techniques
to isolate renal endothelia or leukocytes using beads coated
with specific antibodies for endothelial cells or leukocytes.
This technique, validated in our previous publication,5
confirmed that over 95% of PTX3 was on endothelia
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Figure 1 |Pentraxin 3 (PTX3) deficiency ameliorates ischemic acute kidney injury (AKI). Renal pedicles of PTX3 knockout (KO) mice and
wild-type (WT) littermates were clamped for 16min. Blood samples were collected on days 1, 3, 5, and 7 reperfusion. Day 0 indicates
samples from mice without operation. (a) Blood urea nitrogen (BUN) was measured using a colorimetric method. (b) Serum creatinine
was measured using a capillary electrophoresis method. Error bars represent mean±s.e.m., n¼ 5 per group, *Po0.05 WT day 1 vs. day 0;
NS, not significant PTX3 KO day 1 vs. day 0. (c) Hematoxylin and eosin (H&E) and myeloperoxidase (MPO) staining: at 24-h reperfusion,
kidneys were harvested and fixed in formalin. H&E and MPO stainings were performed on paraffin sections. Arrow shows one of
many damaged tubules. Original magnification,  10. Arrowhead indicates one of many positively staining cells for MPO ( 20). (d) Injury
index at 24-h reperfusion: tissue damage was scored in the cortex and outer medulla (OM). (e) Leukocyte infiltration at 24-h reperfusion. The
number of inflammatory cells in cortex and OM was counted. In both d and e, error bars represent mean±s.e.m., n¼ 5 per group, *Po0.05
WT vs. KO. h.p.f., high-power field.
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(Supplementary Figure S3A and Supplementary Text online).
Furthermore, our in vitro studies, discussed in the next
section, also support the expression of PTX3 on endothelia.
Endothelial PTX3 is regulated by TLR4 and ROS
We studied the regulation of PTX3 in the MS1 endothelial cell
line, primary renal endothelial cultures (ECs) from WT mice,
and mice with conditional KO of MyD88 on endothelia.
Regulation of PTX3 by TLR4 and ROS in MS1 endothelial cells
in vitro. HMGB1 and ROS are potential signals for
endothelial PTX3 production during ischemic AKI. Injured
and dying renal cells release intracellular HMGB1 into the
extracellular space where it has proinflammatory proper-
ties.15 We previously demonstrated that HMGB1 ligated
endothelial TLR4 during ischemic AKI and induced the
expression of endothelial adhesion molecules necessary for
maladaptive inflammation.5 In addition to HMGB1, ROS is
produced during ischemic AKI and elicits maladaptive
responses.16–18 Figure 5a shows that recombinant human
high-mobility group protein B1 (rhHMGB1) increases PTX3
expression by MS1 cells in vitro by 1.6±0.3-fold. As a
positive control, we found that MS1 cells also responded by
1.9±0.4-fold to ultrapure lipopolysaccharide (LPS) that is
the exogenous ligand for TLR4. To test the hypothesis that
endothelial cells will produce more PTX3 under oxidative
stress, we treated MS1 cells with H2O2 at 100 mmol/l for
30 min and replenished cells with complete medium for 4 h in
vitro. This is to mimic the in vivo IRI scenario. H2O2 induced
PTX3 on MS1 by 5.0±1.2-fold (Figure 5b). Figure 5c shows
that rhHMGB1 or LPS enhanced the PTX3 expression
induced by H2O2.
PTX3 is regulated by TLR4 and ROS in primary renal
endothelial cell cultures. The MS1 endothelial cells mentioned
above were originally derived from mouse pancreas,19,20 and
may not accurately reflect renal endothelial cells. We therefore
developed techniques to isolate renal endothelial cells and
study their PTX3 expression. We isolated CD31þ cells from
renal digests and established a primary EC culture. When put
into EC culture medium, CD31þ cells started to grow into
small cell clusters within 3 days. By day 8, cells would reach
confluence and had the signature ‘cobblestone’ appearance of
endothelial cells (Figure 6a). We did not notice any growth
difference between cells harvested from normal kidneys or
ischemic kidneys. We used passage 1 for our experiment.
Figure 6b showed that PTX3 was upregulated in the
presence of H2O2 (1.5±0.2-fold), rhHMGB1 (1.7±0.2 fold),
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Figure 2 |Pentraxin 3 (PTX3) protein increases in kidney and plasma during acute kidney injury (AKI). Renal pedicles of wild-type
mice were clamped for 16min. Kidney samples were collected from normal kidneys and ischemic kidneys harvested at 4 h, day 1, day 3, day
5, and day 7 reperfusion. Tissues were disrupted using a homogenizer in RIPA buffer supplemented with protease inhibitors. Kidney protein
concentration was determined by the Bradford assay in triplicate, and the same amount of protein from each kidney was assayed. Plasma
and kidney PTX3 levels were measured using the Quantikine PTX3 immunoassay kit from R&D Systems. (a) Time-course study of kidney
PTX3. Error bars represent mean±s.e.m., n¼ 4, *Po0.001 compared with sham at each time point. (b) Time-course study of plasma PTX3.
Error bars represent mean±s.e.m., n¼ 4 per group, *Po0.01 vs. sham at the same time point. Plasma PTX3 at 4-h reperfusion was
highlighted in rectangle, and shown in the box. IRI, ischemia-reperfusion injury.
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or LPS (1.9±0.3 fold). Combined treatment of H2O2 and
rhHMGB1 (2.1±0.1 fold), or H2O2 and LPS (3.6±0.2 fold),
induced a much higher level of PTX3.
MyD88 conditional KO on the endothelium decreases PTX3
expression and other markers of endothelial activation. Our
observations above suggest that PTX3 is regulated, in part, by
TLR4. To better understand this regulation, we examined
PTX3 expression with a conditional endothelial MyD88 KO
mouse. MyD88 is required for one of the two major pathways
of TLR4 intracellular signaling, and contributes to the
pathogenesis of ischemic AKI.21–23 To delete MyD88 on endo-
thelial cells (‘conditional MyD88 KO’), we used an established
mouse with floxed MyD8824 and the Tie2Cre mouse25,26 that
expresses cre-recombinase uniquely on endothelia during
ischemic AKI.13,14 The MyD88 KO mouse is normal, except
in its responses to infection and injury.27 Baseline renal and
plasma PTX3 levels were similar in the ‘conditional MyD88
KO’ and MyD88 f/f; Tie2Cre() (‘WT’) mice. Using this cre-
lox strategy, we were able to knock out MyD88 from renal
endothelial cells by 50%. Despite this substantial residual
endothelial MyD88, we found dramatic phenotypes with
regard to renal and plasma PTX3 protein after IRI, as well as
in endothelial activation markers.
The main point of these studies was that at 18-h reper-
fusion there was much less renal PTX3 protein in the
‘conditional MyD88 KO’ kidneys (21.9±2.3 ng/ml) than
in ‘WT’ kidneys (33.8±2.8 ng/ml); see Figure 7a. This
decreased PTX3 in ischemic ‘conditional MyD88 KO’ kidneys
was associated with decreased plasma PTX3 at 18-h
reperfusion (341.0±12.2 ng/ml) compared with ‘WT’ plasma
(480.0±15.9 ng/ml); see Figure 7b. The decreased plasma
PTX3 confirms the decreased production in the ‘conditional
KO’ kidneys. These studies suggest that endothelial PTX3 is
regulated by the endothelial MyD88-dependent pathway of
TLR4 signaling during ischemic AKI.
There was a much smaller increase in renal and plasma
PTX3 after sham surgery in both ‘conditional MyD88 KO’
and ‘WT’ mice. Because this increase was the same in both
types of mice, we believe that it was independent of
endothelial Myd88 and was due to cytokine released from
the surgical trauma to skin and muscle that was common to
both groups of mice and necessary to expose the renal
pedicle. Cytokines such as tumor necrosis factor-a are known
to regulate PTX3 production.6 These results are consistent
with the idea that the uninjured kidney responds to cytokines
produced by injured distant tissues.28
Another major point of Figure 7 is the inhibitory effect of
‘conditional MyD88 KO’ on endothelial adhesion molecules.
In WT kidneys, such adhesion molecules are required for
the inflammatory response to IRI that exacerbates injury.5
Figure 7c shows that after IRI, endothelial cells isolated
from ‘WT’ endothelia increased their expression of ICAM1
(2.3±0.2-fold), VCAM1 (2.3±0.8-fold), E-selectin (3.5±
0.3-fold), and P-selectin (2.2±0.1-fold). In contrast, endo-
thelia isolated from ‘conditional MyD88 KO’ mice did not
increase these adhesion molecules. Furthermore, ‘WT,’ but
not ‘conditional MyD88 KO,’ endothelia increased their
expression of ESM1 (5.9±0.4-fold), which is uniquely found
on endothelia,29 NOS3 (3.5±0.2-fold), and fibroblast growth
factor 2 (FGF2) (3.9±0.3-fold). Note that ESM1 expression
after IRI was also decreased in TLR4-deficient kidneys
(Figure 3). All of the three molecules are thought to ameliorate
ischemic AKI.29–33 Finally, to our knowledge, these are the first
studies to demonstrate increased expression of ESM1, NOS3,
FGF2, CXCL4, and CXCL1 on renal endothelia isolated
after IRI.
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Figure 3 | Toll-like receptor 4 (TLR4) is required for increased
pentraxin 3 (PTX3) in acute kidney injury (AKI). Renal pedicles
of wild-type (WT) B10 and TLR4 knockout (KO) mice were clamped
for 23min and kidneys harvested at 4-h reperfusion. The genes of
interest (PTX3, EsM1, and TLR4) were determined by quantitative
reverse transcription PCR and analyzed by the comparative Ct
method. The calibrator gene is the gene of interest taken from
the sham kidney. (a) WT kidneys. (b) TLR4 KO kidneys. Error bars
show mean±s.e.m., n¼ 6 in each group, *Po0.01 ischemia-
reperfusion injury (IRI) compared with sham; NS, not significant.
(c) Immunohistology shows increased PTX3 in WT kidneys at 4-h
reperfusion. A rat anti-mouse PTX3 monoclonal antibody was
used to stain frozen sections from paraformaldehyde-fixed tissues.
Exactly the same staining conditions and exposures were used to
compare PTX3 expression in sham and AKI kidneys. PTX3 is
located on peritubular capillaries of the outer medulla. PTX3 was
increased on WT ischemic kidneys. No increased endothelial PTX3
was found on ischemic TLR4 KO kidneys ( 40). Arrows indicate
some of many capillaries positive for PTX3; ‘T’ indicates a few of
many tubules. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase.
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PTX3 KO differentially changes endothelial function
at 4 vs. 24 h after renal IRI
The data given below show that PTX3 KO profoundly alters
the biology of renal endothelial cells during ischemic AKI.
This may explain how PTX3 KO ameliorates this disease.
Using anti-CD31-conjugated Dynabeads, we isolated and
compared renal endothelial from WT vs. PTX KO mice at 4-h
and 24-h reperfusion. We found that PTX3 KO had opposite
effects at these two time points.
At 4-h reperfusion, inflammation exacerbates ischemic
injury.34,35 We previously showed that at this time WT
endothelia increased their expression of adhesion molecules
(ICAM1, VCAM1, E-selectin), and that TLR4 KO prevented
maladaptive inflammation by preventing such adhesion
molecule expression.5 Figure 8a shows that PTX3 KO also
prevented the expression of these adhesion molecules. We also
examined other endothelial activation markers. Similar to the
conditional MyD88 KO (Figure 7c) and unlike the WT
endothelial cells, PTX3 KO did not increase the expression of
ESM1 or NOS3. These data suggest that PTX3 is downstream
of TLR4, and that the expression of these adhesion molecules
is downstream of PTX3.
At 24-h reperfusion, inflammation may have a different
function. Instead of exacerbating injury, late inflammation
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Figure 4 |Pentraxin 3 (PTX3) colocalizes with CD31þ cells on kidney. Renal pedicles of wild-type (WT) mice were clamped for 23min.
Kidney was in situ perfused with 4% paraformaldehyde at 4 h after reperfusion and then snap-frozen. (a) In sham kidney at 4-h post
operation, PTX3 was detected on the peritubular structure in the outer medulla (OM). Representative staining of PTX3 in the conjunction of
cortex–OM area ( 10), OM area ( 20), and OM area ( 40). (b) PTX3 colocalized with CD31 on the kidney section. A rabbit polyclonal anti-
PTX3 was used in a and b. In b, a rat monoclonal antibody was also used to stain for CD31 ( 20), and species-specific secondary antibodies
allowed double staining for PTX3 and CD31. (c) PTX3 was detectable only by a rat monoclonal antibody after ischemia-reperfusion injury
(IRI). At 4-h reperfusion, PTX3 was expressed on glomeruli, peritubular capillaries in both OM and inner medulla (IM;  20). Arrows pointed
to endothelia; ‘T’, tubules, ‘G’, glomeruli. Each stain was carried out on four individual mice per group, and the images in the figures are
representative of each group. See Supplementary Figure S5 for high resolution photomicrographs.
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may inhibit aggressive leukocyte activity, and reparative
macrophages may facilitate repair.36–40 In contrast to the 4-h
reperfusion time point when PTX3 KO endothelial cells
decreased adhesion molecule expression, Figure 8b shows the
PTX3 KO increased expression of the adhesion molecules
ICAM1, VCAM1, and P-selectin. This suggests that PTX3 KO
endothelia may facilitate immigration of regulatory and
reparative leukocytes into the injured kidney.
PTX3 KO alters renal endothelial function in primary cultures
To further explore the effect of PTX3 KO on the renal
endothelium, we developed techniques to isolate and then
culture primary endothelial cells from WT vs. PTX3 KO
kidneys. These primary ECs were then stimulated with the
TLR4 ligands HMGB1 or LPS. As opposed to the endothelia
directly isolated from sham and ischemic kidneys in Figure 8
above, these primary endothelial cells have not been injured
by IRI in vivo, and have been in the presence of growth factors
vascular endothelial growth factor (VEGF), FGF, insulin-like
growth factor 1 (IGF1), hepatocyte growth factor 1 (HGF1),
hydrocortisone, and heparin) that facilitate the survival of
these cells in vitro and attempt to mimic the in vivo
microenvironment. The main point learned from these
primary cultures is that renal endothelia from PTX KO vs.
WT mice are fundamentally different.
Three different groups of endothelial responses were seen
(Figure 9). The first group (ICAM-1, VCAM 1, E-selectin) of
responses were the same in WT and PTX3 KO endothelial
cells. These are proinflammatory adhesion molecules.34,35
The second group (P-selectin, and IL6) comprised responses
present in WT endothelia, but not in PTX3 KO endothelia.
These are also proinflammatory genes that have demon-
strated maladaptive effects during ischemic AKI.41 The lesser
expression of these genes by primary renal endothelia
stimulated by TLR4 ligands in PTX3 KO mice may contribute
to the lesser IRI seen in these mice. The third group (FGF2
and NOS3) comprised responses that were present in PTX3
KO but not WT mice. FGF2 ameliorates ischemic AKI,30,31
and NOS3 should help preserve renal blood flow.32,33
DISCUSSION
We found that KO of PTX3 ameliorated IRI as assessed by both
renal function and morphology. This is consistent with the
detrimental effect of PTX3 on murine gastrointestinal IRI.42,43
This is, however, in contrast to the beneficial effect of PTX3
on murine cardiac IRI. Cardiac IRI exposes a non-muscle
myosin heavy chain II. This is bound by a natural IgM
autoantibody that activates complement the C1q-dependent
classical pathway;44 soluble PTX3 binds soluble C1q and
inhibits such classical pathway activation.45 In contrast, PTX3
has no effect on complement activation during renal IRI.
Renal IRI does activate complement but not by natural
autoantibodies and the classical pathway.46,47 Instead, tubular
injury decreases Crry, the murine homolog of human MCP
(membrane cofactor protein) and DAF (decay accelerating
factor); Crry normally prevents amplification of the alternative
complement pathway after ‘C3 tickover’.48 In the absence of
tubular Crry, alternative complement activation continues
unrestrained and renal tubular injury results.49,50 As shown by
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Figure 5 | Toll-like receptor 4 ligands and reactive oxygen
species increase pentraxin 3 (PTX3) expression in the MS1 cell
line. MS1 cells were cultured in Dulbecco’s modified Eagle’s
mediumþ 10% fetal calf serum until reaching confluence. Cells
were stimulated with (a) recombinant human high-mobility group
protein B1 (rhHMGB1) or lipopolysaccharide (LPS) at 5 mg/ml for
4 h, or (b) H2O2 at 100 mmol/l in Earle’s balanced salt solution for
30min and then replenished with complete medium for 4 h, or
(c) H2O2 at 100mmol/l for 30min and followed by rhHMGB1 or LPS
(5 mg/ml) in complete medium for 4 h. PTX3 messenger RNA
(mRNA) was measured from harvested cells by quantitative
reverse transcription PCR. Error bars show mean±s.e.m., n¼ 5,
*Po0.05 compared with the control group. GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
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others,49 we saw more C3 activation on injured and dead
tubules in WT kidneys after IRI than in PTX3 KO kidneys
(Supplementary Figure S4 online). The C3 was not associated
with endothelia (the location of PTX3). There was decreased
C3 deposition on PTX3 KO tubules; this was secondary to the
decreased tubular injury, not a direct effect of PTX3 KO.
Although PTX3 is expressed by endothelia, leukocytes,
and other tissues,6 we found PTX3 almost exclusively on
endothelia in the kidney by immunohistology (Figure 4) and
by the study of isolated endothelia and leukocytes (see
Supplementary Figure S3A online).
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Figure 6 |Primary culture of renal endothelial cells (ECs).
(a) Images of CD31þ Dynabead-isolated cells from kidney:
primary ECs grown in vitro on day 3 and primary EC at confluence
on day 8. Cells showed typical cobblestone morphology.
(b) Pentraxin 3 (PTX3) messenger RNA (mRNA) on primary EC was
upregulated in vitro by H2O2 (100 mmol/l), and/or recombinant
human high-mobility group protein B1 (rhHMGB1; 5 mg/ml),
and/or lipopolysaccharide (LPS; 5 mg/ml). Error bars show
mean±s.e.m., n¼ 4, *Po0.05, **Po0.001 vs. control.
40 f/f; Tie2Cre-sham
*
NS
NS
*
§
§ §
§
§
§
§
§
§
§
§
*
*
§
*
*
*
NS
f/f; Tie2Cre-IRI
f/f; Tie2Cre+sham
f/f; Tie2Cre+IRI
f/f; Tie2Cre-sham
f/f; Tie2Cre-IRI
Tie2Cre-234 sham
Tie2Cre-234
Tie2Cre+234 sham
Tie2Cre+234
f/f; Tie2Cre+sham
f/f; Tie2Cre+IRI
30
Ki
dn
ey
 P
TX
3 
(ng
/m
l)
Pl
as
m
a 
PT
X3
 (n
g/m
l)
20
10
0
0
100
200
300
400
18
16
14
12
10
Ta
rg
et
 g
en
e/
G
AP
DH
 m
RN
A
8
6
4
2
0
ICA
M1
VC
AM
1
E-s
ele
ctin
P-s
ele
ctin
ES
M1
NO
S3
CX
CL
4
CX
CL
1
FG
F2
My
D8
8
500
600
Normal 4 h 18 h
Reperfusion time
Normal 4 h 18 h
Reperfusion time
Figure 7 |Conditional endothelial knockout of MyD88 decreases
pentraxin 3 (PTX3) production and endothelial activation. Renal
pedicles of ‘Wild-type’ [MyD88f/f;Tie2Cre()] and ‘conditional
MyD88 KO’ [MyD88f/f;Tie2Cre(þ )] mice were clamped for 23min.
(a) Kidney PTX3 was measured by ELISA at baseline, 4-h, and
18-h reperfusion. The right kidney was harvested as control.
(b) Plasma PTX3 was measured by ELISA at the same time points.
In both a and b, the error bars stand for mean±s.e.m., n¼ 3 per
group. The four groups at each time point were analyzed by
one-way analysis of variance, and then pairwise comparisons
made by the Holm-Sidak method. *Po0.05 ischemia-reperfusion
injury (IRI) vs. sham, yPo0.05 IRI MyD88f/f;Tie2Cre() vs. MyD88f/f,
Tie2Cre(þ ) at 18-h reperfusion; NS, not significant. (c) Endothelial
markers were detected by quantitative reverse transcription PCR
on CD31þ cells isolated from kidneys at 4-h reperfusion. Data
were analyzed by the comparative Ct method. The calibrator gene
is the gene of interest taken from the sham kidney. Error bars
stand for mean±s.e.m., n¼ 3 per group, yPo0.05 MyD88f/
f;Tie2Cre() IRI vs. sham, *Po0.05 MyD88f/f;Tie2Cre(þ ) IRI vs.
sham. GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
mRNA, messenger RNA.
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Although we cannot exclude the possibility that some
PTX3 is deposited in the kidney from the blood during
ischemic AKI, the following data show that most of the
increased endothelial PTX3 is produced by endothelial cells.
(a) In Figure 3, the increased PTX3 messenger RNA in WT
TLR4-sufficient ischemic kidneys is correlated with an
increased PTX3 protein found on peritubular endothelia.
This correlation is consistent with renal endothelial produc-
tion of PTX3. (b) In vitro stimulation of endothelia by
HMGB1 and ROS, both present in the ischemic kidney,
activates PTX3 gene expression (Figures 5 and 6). (c) If PTX3
was extravasated from blood into the kidney, one would
expect diffuse PTX3 staining because it binds to apoptotic
cells,51 DNA released by dying cells,52 and extracellular
complexes of tumor necrosis factor–stimulated gene 6/inter-
alpha-trypsin inhibitor/hyaluronan.53,54 The latter are found
in the extracellular matrices of injured kidneys.55,56 Instead,
our immunostaining localized PTX3 protein to endothelia;
this is consistent with its production by these cells. (d)
Finally, our idea that PTX3 is produced locally in the kidney
is consistent with the literature. The literature indicates that
PTX3 is produced locally at sites of inflammation and then
escapes into blood rather than vice versa; this is unlike the
other major member of the pentraxin family, CRP, which is
produced in the liver, enters the blood, and then extravasates
into peripheral tissues.57
We explored both upstream events that regulate renal
endothelial PTX3 as well as downstream events by which
PTX3 regulates renal IRI.
Upstream, TLR4 was one important positive regulator of
PTX3 because PTX3 expression in vivo was increased after IRI
in WT, but not in TLR4-deficient, kidneys. HMGB1, released
by injured cells during renal IRI, is the major ligand for TLR4.
Inhibition of HMGB1 with specific antibodies ameliorates
ischemic AKI.58,59 Although HMGB1 binds to a number of
different receptors,15 TLR4 is the major maladaptive receptor
during ischemic AKI. Thus, direct binding of HMGB1 to
TLR4 has been demonstrated by biophysical techniques;60 KO
of RAGE, the other major receptor for HMGB1, has no effect
on ischemic AKI;61 in contrast, KO or inactivation of natural
mutations of TLR4 in mice ameliorate ischemic AKI.21,23,62,63
In addition, mutations that decrease TLR4 signaling in
humans decrease ischemic AKI after transplantation.64
We found that recombinant HMGB1 increased PTX3
expression both in the MS1 endothelial cell line and WT renal
endothelial primary cultures. Furthermore, we found that
conditional MyD88 KO on endothelia decreased PTX3
protein from 33.8±2.8 to 21.9±2.3 ng/ml at 18-h reperfu-
sion. The residual PTX3 expression might be due to
incomplete KO of endothelial MyD88, or the MyD88-
independent pathways of TLR4 signaling, or ROS released
during IRI. Altogether, our data suggest that PTX3 is
increased on endothelia mainly by HMGB1 acting on TLR4
via the MyD88 signaling pathway.
We also made the important observation that partial
conditional KO of endothelial MyD88 markedly decreased
the expression of endothelial adhesion molecules after renal
IRI; this confirms our previous observation that endothelial
TLR4 is required for endothelial activation,5 and shows that
this is due, in large part, to the MyD88 pathway.
In addition, we found that ROS produced during IRI16–18
also contributes to the increased PTX3 expression. ROS
synergize with the TLR4 ligands, HMGB1 or LPS, to increase
PTX3 expression. To our knowledge, ROS has not previously
been reported to regulate PTX3.
Downstream, we used two different experimental systems
to study the effects of PTX3 on endothelial activation during
ischemic AKI.
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Figure 8 |CD31þ cells from pentraxin 3 (PTX3) KO ischemic
kidneys show delayed endothelial activation. Renal pedicles of
wild-type (WT) and PTX3 knockout (KO) mice were clamped for
23min. CD31-bound Dynabeads were used to isolate endothelial
cells from kidney digest at 4-h and 24-h reperfusion. Endothelial
markers were detected by quantitative reverse transcription PCR
(qRT-PCR) and data were analyzed by the comparative Ct method.
The calibrator gene is the gene of interest taken from the sham
kidney. (a) 4-h reperfusion. (b) 24-h reperfusion. Error bars
represent mean±s.e.m., n¼ 3 per group, yPo0.05 WT ischemia-
reperfusion injury (IRI) vs. WT sham, *Po0.05 PTX3 KO IRI vs. KO
sham. FGF2, fibroblast growth factor 2; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; mRNA, messenger RNA.
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(1) We isolated endothelia from ischemic WT and PTX
KO kidneys. KO of PTX3 prevents the early expression of
endothelial adhesion molecules and chemokines known to
facilitate early maladaptive inflammation.65–69 Altogether,
these data suggest that increased PTX3 is one mediator of
early maladaptive endothelial activation triggered by TLR4
that we previously reported.5 In contrast to the decreased
endothelial adhesion molecule expression at 4 h caused by
PTX3 KO, we found increased expression of these adhesion
molecules compared with WT at 24 h after IRI. This should
facilitate the late influx of leukocytes that participate in tissue
repair and turn off the inflammatory response.36–40 Thus,
our results show that PTX3 KO had different effects at 4-h
reperfusion compared with 24-h reperfusion.
(2) In addition, we also studied primary cultures of renal
endothelia from unmanipulated WT and PTX KO mice. After
stimulation by TLR4 ligands, the responses of the WT and
PTX3 KO primary endothelia could be divided into three
groups. Some activation functions were the same. Expression
of other proinflammatory adhesion molecules required
PTX3. Expression of some endothelial functions, such as
FGF2 and NOS3, which should protect or repair the ischemic
kidney, was increased in the PTX3 KO endothelia.
Each of our two experimental systems has advantages and
disadvantages. The endothelial cells isolated from ischemic
kidneys receive the entire spectrum of signals from the
ischemic environment, but subpopulations may be selected
and functions may be altered by the enzymatic and
mechanical disruption during isolation. The endothelia
grown in primary culture avoid the above problems, but
the artificial extracellular matrix and growth factors (VEGF,
FGF, IGF1, HGF, hydrocortisone, and heparin) may not fully
replicate the microenvironment in vivo.
The main point is that both systems show that PTX3 KO
inhibits maladaptive endothelial responses to TLR4 ligands.
The ‘minor’ differences between the two systems may result
from the following: in vivo, no intracellular signaling
pathway, including that for TLR4, operates in isolation, and
any change in cell functions integrates the ‘cross talk’ between
multiple simultaneous signaling pathways.70–72 In other
words, renal endothelial cells in vivo receive signals from a
variety of growth factors and cytokines during AKI in
addition to TLR4 ligands. Given this complexity, the
profound anti-inflammatory effects of KO of single pathway
(PTX3) are remarkable both in vivo (Figure 8) and after
stimulation in vitro (Figure 9). The differences in a few details
are likely the result of ‘cross talk’ between TLR4 and other
signaling pathways, which are different after stimulation in
vivo and in vitro, and will be the focus of future studies. These
differences include the increase in adaptive FGF2 and NOS3
seen after in vitro stimulation (Figure 9), but not in
endothelia isolated from ischemic kidneys (Figure 8).
In addition, although HMGB1 is a major and the
best studied TLR4 ligand released during ischemic
AKI,21,23,58–60,62,63 other TLR4 ligands such as stress fibronec-
tin73 are expected to be produced and may activate endothelial
TLR4 during ischemic AKI in vivo. Each TLR4 ligand may elicit
a slightly different response,74,75 and contribute to the ‘cross
talk’ discussed above. This is illustrated by the different
responses to HMGB1 and endotoxin in Figure 9.
We suggest that PTX3 may exacerbate the above-
mentioned endothelial stress responses during renal IRI by
binding and inhibiting growth factors that would otherwise
ameliorate endothelial injury and promote repair. The
N-terminus of PTX3 specifically binds and inhibits FGF876
and FGF2.77,78 Such inhibition would have detrimental effects
on renal endothelia because FGF2 ameliorates rodent
ischemic AKI.30,31
Another possibility is that PTX3 increases the exposure of
renal endothelial cells to proinflammatory cytokines by
inhibiting ‘efferocytosis’, which is defined as the phagocytosis
of apoptotic cells and which does not result in the release of
proinflammatory cytokines. Apoptosis is a major type
of cell death during ischemic AKI (see review79). PTX3
inhibits efferocytosis;80–83 such inhibition of apoptotic renal
cells would allow these apoptotic cells to degenerate (die a
post-apoptotic death) and release proinflammatory dama-
ge–associated molecular pattern molecules.84–86 Consistent
with this formulation is the increased necrosis and inflam-
mation we observed in the WT compared with the PTX3
KO ischemic kidneys. The idea that efferocytosis inhibits the
maladaptive inflammatory response to renal IRI is supported
by the beneficial effects of increasing efferocytosis by
injections of MFG-E8 (milk fat globule-EGF factor 8/
lactadherin);87,88 MFG-E8 is a ‘bridging molecule’ that links
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Figure 9 | Fundamental differences in primary cultures of
endothelial cells from wild-type (WT) and pentraxin 3 (PTX3)
knockout (KO) kidneys. Primary renal endothelial culture (EC)
was maintained in Clonetics EGM-2 endothelial cell growth
medium-2. Cells were treated with recombinant human high-
mobility group protein B1 (rhHMGB1) or lipopolysaccharide (LPS)
at 5 mg/ml for 4 h in culture. RNA was extracted and quantitative
reverse transcription PCR performed. Error bars show mean
mean±s.e.m., n¼ 3, yPo0.05 WT treated vs. control, *Po0.05
PTX3 KO treated vs. control. FGF2, fibroblast growth factor 2;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA,
messenger RNA.
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the apoptotic cells to phagocytes, and thus increases
efferocytosis.89
In summary, PTX3 may have fundamental importance for
biology and disease because it has been so conserved during
evolution.6 We have now demonstrated important links
between PTX3 and the renal endothelium, TLR4, MyD88,
and ROS in the pathogenesis of ischemic IRI. We showed that
PTX3 KO ameliorates ischemic AKI. PTX3 expression is
increased via ROS, and a MyD88-dependent TLR4-mediated
mechanism on renal endothelia. PTX3 is required for the
early expression of endothelial adhesion molecules and
chemokines that facilitate the maladaptive inflammatory
response to IRI. PTX3 inhibits the late endothelial expression
of adhesion molecules that may facilitate immigration of
regulatory and reparative leukocytes.
MATERIALS AND METHODS
Mice
Six- to eight-week-old male C57BL/10, TLR4-null mice C57BL/
10ScNJ, MyD88-floxed mice B6.129P2(SJL)-Myd88tm1Defr/J, and
Tie2 Cre ‘driver’ B6.Cg-Tg(Tek-cre)1Ywa/J mice were from The
Jackson Laboratory (Bar Harbor, ME). To avoid non-cell-specific
deletion of floxed alles arising from germ line Cre-recombinase
activity,90 female MyD88f/f mice were interbred with male MyD88f/
f; Tie2Cre(þ ) mice to generate conditional endothelial cell–specific
KO MyD88 mice (MyD88f/f;Tie2Creþ ) and littermate control mice
(MyD88f/f; Tie2Cre). PTX3 KO founders were obtained from Dr
Martin M. Matzuk (Baylor College of Medicine, Houston, TX).
Because of the subfertility of female PTX3 KO mice,91 we bred
heterozygous male and heterozygous female mice. Littermates of
PTX3þ /þ were used as controls. Genomic DNA from offspring
was extracted using the Extract-N-Amp Tissue PCR kit (Sigma,
Saint Louis, MO). Primers for genotyping were described in detail in
Supplementary Table S1 online.
Renal IRI
After right nephrectomy, the left renal pedicle was occluded for
either 16 or 23 min; sham-operated mice were used as controls.5 All
mouse work was approved by the UT Southwestern Institutional
Animal Care and Use Committee.
DNA microarray
Detailed methods can be found in the Supplementary Materials
online.
Renal function
Scr was measured using the P/ACE MDQ Capillary Electrophoresis
System with a PDA Detector (Beckman Coulter, Indianapolis, IN).9
Blood urea nitrogen was measured using the VITROS BUN slides on
VITROS 250 Chemistry Analyzer (Ortho Clinical Diagnostics,
Raritan, NJ).
Histology and immunohistology
For histology, kidneys were harvested at 24-h reperfusion and fixed
in 10% neutral-buffered formalin (Sigma). Paraffin-embedded
sections were stained with hematoxylin and eosin and anti-
myeloperoxidase (rabbit anti-myeloperoxidase polyclonal antibody,
Thermo Scientific, Rockford, IL). Tissue damage and inflammation
was evaluated as previously reported.53 For immunofluorescence
staining, mice were in situ perfused with cold PBS followed by cold
4% PFA. Detailed sample processing can be found in our previous
report.5 Sections were blocked with 10% goat serum and stained
with rat anti-mouse Pentraxin 3 mAb (clone 265629, R&D Systems,
Minneapolis, MN) or rat anti-mouse Complement component 3
mAb (clone RmC11H9, Cedarlane Laboratories, Burlington, NC).
Rat IgG2b or IgG2a was used as isotype control. For double staining
of CD31 and PTX3, rat anti-mouse CD31 mAb (clone MEC13.3,
BD Pharmingen, San Diego, CA) was applied to the section
followed by Texas Red–conjugated goat anti-rat IgG (Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit anti-human PTX3 pAb
(which cross reacts with mouse and rat, Santa Cruz Biotechnology),
and then fluorescein goat anti-rabbit IgG (Santa Cruz Biotech-
nology). Sections were mounted with VECTASHIELD Mounting
Medium with 40-6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA), and visualized using a Carl Zeiss Axioplan2
Imaging microscope (Carl Zeiss MicroImaging, Thornwood,
NY). Each staining was carried out on four individual mice
per group and the images in the figures are representative of each
group.
Isolation of endothelial cells and leukocytes
Detailed procedure can be found in our previous reports.5,53
Primary renal endothelial cell culture
Bead-bound CD31þ cells isolated from kidneys were resuspended
in Clonetics EGM-2 endothelial cell growth medium-2 BulletKit
(Lonza, Allendale, NJ) and plated into BD BioCoat Fibronectin
24-well Multiwell plate (BD Pharmingen). Medium was changed
every 3 days. Primary culture passage 1 cells were used for
experiment.
Hydrogen peroxide (H2O2), LPS, rhHMGB1 treatment
Confluent MS1 monolayers or primary renal endothelial cells were
washed with Dulbecco’s phosphate-buffered saline three times. Cells
were exposed to H2O2 (Sigma) at 100mmol/l for 30 min in Earle’s
balanced salt solution at 37 1C, then replenished with complete
medium containing 10% fetal calf serum. Some cells were treated
with rhHMGB1 (R&D Systems) at 5 mg/ml or with an ultrapure
form of LPS that activates only TLR4 (Escherichia coli 0111:B4,
InvivoGen, San Diego, CA) for an additional 4 h, followed by RNA
extraction using the RNeasy Mini kit (Qiagen, Valencia, CA).
Real-time reverse transcription PCR
Detailed procedure can be found in our previous reports.5,53 PCR
primers are listed in Supplementary Table S2 online.
Enzyme-linked immunosorbent assay (ELISA)
Blood and kidney samples were collected at 4, 18, 24 h, day 2, day 3,
day 5, and day 7 reperfusion. Plasma was obtained by centrifuging
blood samples at 2000 g for 15 min at 4 1C. Kidneys were
homogenized in RIPA buffer supplemented with Protease inhibitor
cocktail (Sigma) on ice. Samples were centrifuged at 12,000 r.p.m.
for 15 min at 4 1C. The protein concentration was measured by
Coomassie Plus (Bradford) Assay Reagent (Thermo Scientific) in
triplicate. All samples were stored at 80 1C until analysis. PTX3
protein of each sample was assayed in duplicate using Mouse
Pentraxin 3 Quantikine ELISA Kits (R&D Systems) according to the
manufacturer’s instructions. Absorbance was read on Pelkin Elmer
1420 Multilabel Counter Victor3 plate reader (Pelkin-Elmer,
Waltham, MA) at 450 nm, with correction wavelength set at 540 nm.
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Western blot analysis
Protein extracts were separated by 10% precast SDS-polyacrylamide
gel electrophoresis, transferred to a polyvinylidene difluoride
membrane (Millipore, Billerica, MA), probed with goat anti-mouse
C3 pAb (ICL, Portland, OR) or rat anti-mouse C3 mAb (RMC11H9,
Cdarlane Labs), exposed to a horseradish peroxidase-conjugated
secondary antibody (Sigma), and visualized using Pierce ECL
Western Blotting Substrate (Thermo Scientific) according to
the supplier’s instructions. The beta Actin Antibody (horseradish
peroxidase; GenScript, Piscataway, NJ) was used as loading
control.
Statistics
The data were presented as mean±s.e.m. One-way analysis of
variance Holm-Sidak method and two-tailed Student’s t-test were
carried out using SigmaPlot 11.0. Differences with a P value o0.05
were considered statistically significant.
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